Sonodynamic Therapy with ExAblate System in Glioblastoma Patients (Sonic ALA)
A Pilot Study to Evaluate the Safety and Feasibility of Sonodynamic Therapy Using the ExAblate MRI-Guided Focused Ultrasound in the Treatment of Cerebral Glioblastomas.
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
A PHASE2 clinical study on Glioblastoma Multiforme, this trial is completed. The trial is conducted by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE2
Status: Not Yet Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
Phase: NA → PHASE2
-
Feb 2022 — Feb 2023 [monthly]
Not Yet Recruiting NA
▶ Show 1 earlier version
-
May 2021 — Feb 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
For direct contact, visit the study record on ClinicalTrials.gov .